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Heart Failure
Evaluation of Bromocriptine in the Treatment of Acute
Severe Peripartum Cardiomyopathy
A Proof-of-Concept Pilot Study
Karen Sliwa, MD, PhD; Lori Blauwet, MD; Kemi Tibazarwa, MD; Elena Libhaber, PhD;
Jan-Peter Smedema, MD, MMed(Int); Anthony Becker, MD; John McMurray, MD, FESC;
Hatice Yamac, MD; Saida Labidi, MSc; Ingrid Struman, PhD; Denise Hilfiker-Kleiner, PhD
Background—Peripartum cardiomyopathy (PPCM) is a potentially life-threatening heart disease that occurs in previously
healthy women. We identified prolactin, mainly its 16-kDa angiostatic and proapoptotic form, as a key factor in PPCM
pathophysiology. Previous reports suggest that bromocriptine may have beneficial effects in women with acute onset of
PPCM.
Methods and Results—A prospective, single-center, randomized, open-label, proof-of-concept pilot study of women with
newly diagnosed PPCM receiving standard care (PPCM-Std; n10) versus standard care plus bromocriptine for 8 weeks
(PPCM-Br, n10) was conducted. Because mothers receiving bromocriptine could not breast-feed, the 6-month
outcome of their children (n21) was studied as a secondary end point. Blinded clinical, hemodynamic, and
echocardiographic assessments were performed at baseline and 6 months after diagnosis. Cardiac magnetic resonance
imaging was performed 4 to 6 weeks after diagnosis in PPCM-Br patients. There were no significant differences in
baseline characteristics, including serum 16-kDa prolactin levels and cathepsin D activity, between the 2 study groups.
PPCM-Br patients displayed greater recovery of left ventricular ejection fraction (27% to 58%; P0.012) compared
with PPCM-Std patients (27% to 36%) at 6 months. One patient in the PPCM-Br group died compared with 4 patients
in the PPCM-Std group. Significantly fewer PPCM-Br patients (n1, 10%) experienced the composite end point of poor
outcome defined as death, New York Heart Association functional class III/IV, or left ventricular ejection fraction
35% at 6 months compared with the PPCM-Std patients (n8, 80%; P0.006). Cardiac magnetic resonance imaging
revealed no intracavitary thrombi. Infants of mothers in both groups showed normal growth and survival.
Conclusions—In this trial, the addition of bromocriptine to standard heart failure therapy appeared to improve left
ventricular ejection fraction and a composite clinical outcome in women with acute severe PPCM, although the number
of patients studied was small and the results cannot be considered definitive. Larger-scale multicenter and blinded
studies are in progress to test this strategy more robustly. (Circulation. 2010;121:1465-1473.)
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Peripartum cardiomyopathy (PPCM) is characterized bynew onset of heart failure between 1 month before and 5
months after delivery in previously healthy women.1 The
clinical presentation and management of PPCM and its
outcome have been reviewed recently.1,2 Only 23% to 54% of
patients show recovery of cardiac function within 6
months.3–6 Investigation of a large cohort of PPCM patients
demonstrated that this condition is associated with a proin-
flammatory response, as evidenced by elevated plasma levels
of tumor necrosis factor-, Fas-Apo-1, interleukin-6, and
C-reactive protein (CRP).5,7,8
Editorial see p 1463
Clinical Perspective on p 1473
We recently reported that enhanced oxidative stress in a
mouse model for PPCM (mice with a cardiac-specific dele-
tion for signal transducer and activator of transcription-3)
triggers the activation of cathepsin D, a ubiquitous lysosomal
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enzyme that subsequently cleaves serum prolactin into its
antiangiogenic and proapoptotic 16-kDa form.9 This is asso-
ciated with endothelial inflammation, impaired cardiomyo-
cyte metabolism, and reduced myocardial contraction, sug-
gesting that oxidative stress, inflammation, and prolactin may
be interconnected and responsible for initiating PPCM.
Similarly, we found evidence for increased oxidative
stress, enhanced cathepsin D activity, and increased prolactin
cleavage in patients with acute PPCM.9 More recently, we
documented a close correlation between N-terminal brain
natriuretic peptide (NT-proBNP; a marker of ventricular wall
stress and heart failure), prolactin, and markers of oxidative
stress (oxidized low-density lipoprotein) and inflammation
(interferon-), further supporting the detrimental role of the
oxidative stress–prolactin axis.10
Importantly, blockade of prolactin with the dopamine-2D
agonist bromocriptine prevented the onset of PPCM in mice
and in 6 women at high risk of this condition as a result of
documented PPCM in a previous pregnancy.9 Several case
reports have also described seemingly beneficial effects from
the addition of bromocriptine to standard heart failure therapy
in patients with acute PPCM.9,11,12 Although these prelimi-
nary results suggesting beneficial effects of bromocriptine
treatment in patients with acute PPCM appear promising,
concerns have been raised about the risk of thrombotic
complications, including cerebral vascular incident and myo-
cardial infarction, related to bromocriptine therapy13–16 and
the consequences for the children of these patients because
the mothers are unable to breast-feed.17
The present work summarizes data from the first random-
ized study to assess the efficacy of bromocriptine on recovery
of left ventricular (LV) function, symptom status, and other
clinical measures in patients presenting within the first month
postpartum with new-onset symptomatic PPCM and an LV
ejection fraction (LVEF)35%. The progress of the newborn
children over the 6-month follow-up period was also studied.
All open-label efficacy assessments were made by indepen-
dent blinded investigators.
Methods
Study Design and Patient Recruitment
This study was approved by the Human Research Ethics Committee
of the University of the Witwatersrand, Johannesburg, South Africa,
and complies with the Declaration of Helsinki. All patients and
control subjects gave written informed consent before study entry.
Twenty consenting consecutive patients diagnosed with PPCM and
fulfilling the inclusion criteria were enrolled in the study. All patients
were included and randomized with a computer-generated random-
ization list within 24 hours of diagnosis.
The study was conducted at the Chris Hani Baragwanath
Hospital. Patients were referred from local clinics, secondary
hospitals, and the Department of Obstetrics at the Chris Hani
Baragwanath Hospital. History of preexisting cardiac symptoms
and signs, occurrence of preeclampsia, and mode of delivery were
obtained from the patient and confirmed by examination of the
obstetric card carried by each patient. Symptoms and signs were
recorded during first presentation at the cardiac unit at the Chris
Hani Baragwanath Hospital (baseline) and after a follow-up
period of 6 months. Clinical assessment, echocardiography, and
blood analysis were performed at baseline and at 6 months.
Cardiac magnetic resonance imaging (MRI) was obtained 4 to 6
weeks after diagnosis in patients receiving bromocriptine.
Inclusion criteria were symptoms of congestive heart failure that
developed in the last month of pregnancy or during the first month
postpartum, no other identifiable cause for heart failure, and LVEF
















1 PPCM-Std 23 2 25 6.25 10 80 25
4 PPCM-Std 21 2 18 12.5 10 80 25
5 PPCM-Std 22 1 20 6.25 5 80 25
9 PPCM-Std 46 3 21 12.5 10 120 50
10 PPCM-Std 24 2 26 25 10 80 25
12 PPCM-Std 21 1 26 6.25 5 80 0
13 PPCM-Std 24 1 22 25 10 80 25
16 PPCM-Std 44 6 28 12.5 5 80 0
17 PPCM-Std 18 1 12 6.25 5 80 0
20 PPCM-Std 38 3 7 12.5 10 80 25
2 PPCM-Br 22 2 8 6.25 5 80 25
3 PPCM-Br 38 3 14 6.25 5 80 12.5
6 PPCM-Br 24 1 26 12.5 5 80 25
7 PPCM-Br 22 2 7 6.25 5 80 25
8 PPCM-Br 18 2 24 6.25 5 80 25
11 PPCM-Br 24 2 7 6.25 10 120 25
14 PPCM-Br 23 1 4 25 5 80 50
15 PPCM-Br 28 1 30 25 5 80 25
18 PPCM-Br 22 1 2 6.25 5 80 25
19 PPCM-Br 18 1 3 12.5 5 120 0
LVEDD indicates LV end-diastolic diameter; CHF, congestive heart failure; and NR, not reported.
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35% by transthoracic echocardiography. Exclusion criteria were
systolic blood pressure 160 or 95 mm Hg or diastolic
105 mm Hg; clinical conditions other than cardiomyopathy that
could increase plasma levels of inflammatory markers such as sepsis,
autoimmune disease, or HIV positivity; significant liver disease
(defined as liver transaminase levels 2 times the upper limit of
normal); history of peptic ulcer disease; history of psychiatric
disorders; impaired renal function (defined as urea and/or creatinine
1.5 times the upper limit of normal); and any clinical condition
that, according to the investigators, precluded inclusion in the study
such as ischemic heart disease or malignancy.
All patients received treatment with the diuretic furosemide and
the angiotensin-converting enzyme (ACE) inhibitor enalapril.
Patients with an LVEF 25% or LV thrombus received antico-
agulation therapy with warfarin for 6 months. Carvedilol was
added after resolution of overt heart failure. Enalapril and
carvedilol doses were titrated upward as tolerated during the first
4 weeks after diagnosis and then remained unchanged throughout
the remainder of the 6-month study period. Furosemide dose was
decreased as indicated according to clinical assessment during the
6-month study period. The 10 patients randomized to standard
therapy (PPCM-Std group) were treated as outlined above. The 10
patients randomized to standard therapy plus bromocriptine
(PPCM-Br) received bromocriptine 2.5 twice daily for 2 weeks
followed by 2.5 mg daily for 6 weeks in addition to standard heart
failure therapy. After the initial screening and baseline visits,
monthly outpatient visits were scheduled for clinical assessment
and evaluation of medication compliance.
Echocardiography, Cardiac MRI, Assessment of
New York Heart Association Functional Class, and
Noninvasive Blood Pressure Measurements
Patients were diagnosed by specialist physicians and cardiologists
working at the Chris Hani Baragwanath Hospital. Patients were
included in this trial within 24 hours after diagnosis once the
diagnosis was confirmed by a cardiologist (K.S.), who repeated the
echocardiography. Two-dimensional and targeted M-mode echocar-
diography with Doppler color-flow mapping was performed with
either a Hewlett Packard Sonos 5500 (Royal Philips Electronics,
Amsterdam, the Netherlands) or a VIVID i (General Electric
Company, Fairfield, Conn) echocardiography machine. Systolic and
diastolic LV dimensions were measured according to the American
Society of Echocardiography guidelines.18 Measurements of LV
dimensions and function were determined by use of the average of
3 cycles. Mitral effective regurgitant orifice area and Doppler
parameters of diastolic function were measured according to Amer-
ican Society of Echocardiography guidelines.19,20 Echocardiography
was recorded on video or a compact disk and stored within the
Soweto Cardiovascular Research Unit Division for further reference,
audit purposes, and repeat blinded analysis by a single operator.
Cardiac MRI was performed 4 to 6 weeks after diagnosis in
patients receiving bromocriptine to detect possible mural thrombi.
Studies were performed with a 1.5-T MRI scanner (General Electric,
Milwaukee, Wis) with a cardiac-dedicated phased-array coil. The
cardiac MRI studies were ECG triggered by standard software.
Studies consisted of steady-state free precession and spin echo.
Short-axis, transverse, and coronal views were obtained. Steady-state
free-precession sequences were performed to assess regional wall
motion abnormalities and LVEF. Slice thickness was 8 mm with no
gap, 256256 matrix, 400-mm field of view, and 1.61.68-mm
voxel size. The total time required for the investigation was 30 to 45
minutes. Gadolinium enhancement was not studied. Ventricular
parameters were assessed in a standard manner by 1 observer using
commercially available software (CAAS MRV, Pie Medial Imaging,
Maastricht, the Netherlands). The cardiac MRI studies were assessed
by 2 independent experienced observers who determined the pres-
ence or absence of intracavitary thrombi.
New York Heart Association (NYHA) functional class of each
patient at baseline and follow-up visits was evaluated by a physician
who was provided clinical data but was blinded to treatment
allocation and was unaware of the results of the laboratory tests.
Heart rate and systolic and diastolic blood pressures were measured

















6 mo, % Prespecified End Point of Poor Outcome
54 60 III III 46 43 33 40 Yes
11 NR II NR 61 NR 28 NR Yes (died 1 mo after baseline of sudden death)
9 NR IV NR 65 NR 18 NR Yes (died 1 mo after baseline of CHF)
16 16 IV III 62 60 24 22 Yes
50 48 II II 60 62 19 24 Yes
50 9 II I 59 52 34 50 No
5 NR II NR 62 NR 34 NR Yes (died 3 mo after baseline of CHF)
233 7 III III 57 43 32 44 Yes
52 NR IV NR 59 NR 14 NR Yes (died on index admission)
30 8 II II 60 74 32 37 No
135 8 IV I 33 44 34 58 No
122 6 II I 65 59 29 37 No
22 7 II I 68 65 30 62 No
56 7 II I 54 51 27 72 No
4 6 II I 56 48 30 56 No
91 25 III I 63 51 30 58 No
55 8 IV I 55 47 33 60 No
18 13 II I 49 34 32 75 No
NR NR III NR 55 NR 18 NR Yes (died on index admission)
5 12 III I 54 56 8 48 No
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and calculated as mean values from 5 readings. Measurements were
made after a 30-minute resting period in patients in the sitting
position with 2-minute intervals between successive measurements.
Research-Specific Blood Tests
Blood (8 mL) was withdrawn from an antecubital vein, collected in
prechilled tubes containing EDTA acid or clot activator, and mixed
rapidly. Plasma or serum was separated by centrifugation at 2500
rpm for 7 minutes within 10 minutes of collection. Aliquots were
stored at 80°C for possible future analysis. High-sensitivity CRP
(hsCRP) was measured as described previously.5,7,8 In addition,
prolactin, NT-proBNP, full blood count, liver function, and creati-
nine were measured. Serum levels of 16-kDa prolactin were mea-
sured by immunoprecipitation followed by Western blotting. Cathep-
sin D activity was assayed with the Sensolyte 520 Cathepsin D Assay
Kit (MoBiTec) as previously described.9
Analysis of Outcome
The prespecified combined end point of poor outcome was defined
as death, NYHA functional class III/IV, or LVEF35% at 6 months
as previously described.8
Assessment of Children
Standard growth monitoring charts issued by the South African
Department of Health and maintained by primary physicians were
obtained for the newborn children of mothers included in this study.
These charts listed the weight of each child at birth and at regular
intervals to 6 months and beyond. Weights were plotted on World
Health Organization weight-for-age Child Growth Standard charts
for girls and boys.21,22
Statistical Analysis
Data were analyzed with the SAS version 9.1 statistical program
(SAS Institute Inc, Cary, NC). Results are expressed as meanSD or
median (range). Comparison between groups at baseline and within
groups (baseline to 6 months) of class variables was analyzed by 2
test or the Fisher exact test when adequate. NT-proBNP data were
log transformed. To assess differences between the 2 treatment
groups, we analyzed mean changes (baseline to 6 months) in all
continuous variables with a t test or an exact Wilcoxon 2-sample test
when distribution was not normal. For within-group comparisons, a
paired t test or a sign test when distribution was not normal was
performed. Significance was assumed at a 2-sided value of P0.05.
Results
Baseline Characteristics and Treatment
Ninety-three patients with suspected PPCM were screened to
recruit 20 consecutive patients with confirmed PPCM who were
HIV negative and presented within 1 month postpartum. As
depicted in Tables 1 and 2, the baseline characteristics of patients
in the PPCM-Br and PPCM-Std groups were similar in terms of
age, parity, NYHA functional class, systolic and diastolic blood
pressures, heart rate, LV end-diastolic and end-systolic dimen-
sions, and LVEF. Median prolactin and median NT-proBNP
levels were comparable, whereas serum levels of 16-kDa pro-
lactin and cathepsin D activity were elevated to a similar degree
in all patients (Figure 1).
Treatment with standard heart failure medications was
similar between the PPCM-Br and PPCM-Std groups (Table
1). Median dose of enalapril in the PPCM-Br group was 5
mg/d (range, 5 to 10 mg/d) and in the PPCM-Std group was
10 mg/d (range, 5 to 10 mg/d). Median dose of carvedilol in
the PPCM-Br group was 6.25 mg twice daily (range, 6.25 to
25 mg) and in the PPCM-Std group was 12.5 mg twice daily
(range, 6.25 to 25 mg). Median dose of furosemide at 6
months was 80 mg/d (range, 80 to 120 mg). All patients,
including those with normalized LV systolic function, con-
tinued on medical therapy with ACE inhibitor and carvedilol
during the 6-month study period. Cardiac transplantation or
implantation of a LV assist device is not performed in state
hospital patients in the Gauteng province of South Africa.
Hemodynamic and Echocardiographic Parameters
Changes in systolic and diastolic blood pressures and heart
rate from baseline to 6 months were not significantly different
between the 2 treatment groups. In contrast, recovery of
LVEF between baseline and 6 months was greater in the
PPCM-Br group (31%) than in the PPCM-Std group (9%;
P0.012; Table 3 and Figure 2). Furthermore, the degree of
mitral regurgitation significantly improved in the PPCM-Br
group compared with the PPCM-Std group (P0.013), as did
several parameters of diastolic function (Table 3). No signif-
icant differences were observed in LV end-diastolic and
end-systolic dimension change from baseline to 6 months
between the 2 groups (Table 3).
NYHA Functional Class
All 9 surviving patients in the PPCM-Br group recovered to
NYHA functional class I at 6 months. In contrast, all patients







Age, y 246 2810 0.60







Heart rate, bpm 10213 10815 0.34
NYHA functional class, n (%) 1.00
II 5 (50) 5 (50)
III/IV 5 (50) 5 (50)
Echocardiographic parameters
LVEDD, mm 5510 595 0.25
LVESD, mm 469 526 0.16
LVEF, % 27.28.1 26.97.6 0.87
Mitral regurgitation (grade) 2.10.6 1.90.6 0.70
Mitral ERO, cm2 0.450.13 0.440.18 0.90
Laboratory parameters
Hemoglobin, g/dL 13.02.2 11.81.9 0.22
Creatinine, mol/L† 71 (6–109) 66 (5–96) 0.43
hsCRP, mg/L† 7.8 (1.1–58.0) 6.0 (4.0–115.3) 0.86
Prolactin, g/L† 49.9 (3.8–135.0) 30.0 (5.1–233.0) 0.87
Log NT-proBNP 8.541.14 8.451.24 0.88
LVEDD indicates LV end-diastolic diameter; LVESD, LV end-systolic diame-
ter; and ERO, effective regurgitant orifice.
*Values are meanSD unless otherwise specified.
†Values are median (range).
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from the PPCM-Std group who survived 6 months were in
NYHA functional class II (3 patients) or III (3 patients)
(Tables 1 and 4).
Survival
The single patient who died in the PPCM-Br group presented
in severe heart failure and survived only 7 days. All 9
remaining patients in the PPCM-Br group survived 6 months.
Four patients in the PPCM-Std group died during the 6-month
follow-up period: 1 died of heart failure during the index
admission, 2 died of heart failure 4 to 12 weeks after
diagnosis, and 1 experienced sudden cardiac death 1 month
after baseline assessment.
Laboratory Parameters
There was a difference in change of log NT-proBNP levels
from baseline to 6 months of borderline statistical signifi-
cance in the PPCM-Br patients compared with the PPCM-Std
patients (P0.05), whereas the reductions in prolactin and
hsCRP levels at 6 months were similar between the 2 groups
(Table 5).
Figure 1. Analysis of prolactin subforms
and cathepsin D activity in baseline serum
probes from PPCM patients. A, Represen-
tative Western blot showing 16-kDa pro-
lactin immunoprecipitated from serum
probes of PPCM patients and from serum
of a nulliparous (NP) control. Bar graph
depicts 16-kDa prolactin serum levels in
PPCM-Std (Std; n7) and PPCM-Br (Br;
n8) vs the mean value of NP (n3),
which was set at 100% (**P0.01 vs NP).
B, The specificity of the immunoprecipita-
tion (IP) was confirmed with anti-prolactin
antibodies (Prl), nonspecific immunoglobu-
lin G (IgG), and no antibody (neg) in a
PPCM serum probe, followed by detection
of 16-kDa prolactin by Western blot. C,
Bar graph depicting cathepsin D activity in
serum probes from PPCM patients
(PPCM-Std, n8; PPCM-Br, n9) at
baseline and in NP (n7). Mean value of
NP was set at 100% (**P0.01 vs NP).










Systolic blood pressure, mm Hg 11623 11813 11019 1159 0.78
Diastolic blood pressure, mm Hg 7016 749 7618 736 0.77
Heart rate, bpm 10213 647 10815 7915 0.22
Echocardiographic parameters
LVEDD, mm 5510 519 595 5612 0.50
LVESD, mm 469 3410 526 4511 0.18
LVEF, % 278 5811 278 3611 0.0007
Mitral regurgitation (grade) 2.10.6 0.220.44 1.90.6 1.51.0 0.0042
Mitral ERO, cm2 0.450.13 0.110.03 0.440.18 0.340.18 0.02
Left atrial diameter, cm 3.540.25 3.360.53 3.830.62 3.930.83 0.25
Mitral E velocity, cm/s 8619 6624 8923 8524 0.53
Mitral A velocity, cm/s 327 4819 336 4512 0.80
Mitral E velocity/A velocity ratio 2.820.76 1.631.13 2.730.68 1.940.67 0.82
Deceleration time, ms 11826 19759 13630 16836 0.08
Mitral medial annular (E) TDI velocity, cm/s 7.01.3 12.42.4 6.51.1 7.32.5 0.014
E/E (medial annular velocity) 12.53.0 5.42.5 14.04.6 12.44.6 0.08
Mitral lateral annular (E) TDI velocity, cm/s 7.21.1 12.42.5 6.60.97 7.32.5 0.007
E/E (lateral annular velocity) 12.02.0 5.42.5 13.84.2 12.13.9 0.051
Abbreviations as in Table 2, plus TDI indicates tissue Doppler imaging.
*Values are meanSD.
†Comparing the change from baseline to 6 months in PPCM-Br and PPCM-Std patients.
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Combined Measure of Poor Outcome
The combined measure of poor outcome that included LVEF
35% (surviving PPCM-Br, 0 of 9 [0%] versus surviving
PPCM-Std, 2 of 6 [33%]), NYHA functional class III/IV at 6
months (surviving PPCM-Br, 0 of 0 [0%] versus surviving
PPCM-Std, 3 of 6 [50%]), or death within 6 months (PPCM-
Br, 1 of 10 [10%] versus PPCM-Std, 4 of 10 [40%]) revealed
that the PPCM-Br patients had better outcome than the
PPCM-Std patients (P0.006; Figure 3).
Thrombi and Thromboembolism
No adverse effects, including thromboembolism, were re-
ported in either group. Cardiac MRI was performed at 4 to 6
weeks after diagnosis in 8 of the 10 patients in the PPCM-Br
group to assess for thrombus formation. MRI results were not
available for 1 patient who died before becoming stable
enough for the MRI, and the images acquired for a second
patient were not of sufficient quality for reliable assessment.
None of the remaining patients had intracavitary thrombi
(Figure 4).
Infant Growth Curves and Survival
All 21 children of the PPCM-Br and PPCM-Std patients
showed normal growth curves when plotted on the World
Health Organization standard weight-for-age growth charts
(Figure 5A and B). Although the survival of all 21 children
through the 6-month follow-up period was verified, weight-
for-age data at 6 months were available for only 13 children.
The mothers of 5 children died during the course of the study
and family members could not provide the children’s growth
charts, and the growth charts of the 3 other children with
missing data were incomplete because of challenges in the
delivery of quality care in the primary healthcare system in
South Africa. However, all children had weight data up to the
age of 3 months, and there were no significant differences in
growth curves between the children of the PPCM-Br patients
and those of the PPCM-Std patients.
Discussion
This prospective, single-center, randomized, open-label pilot
study with blinded efficacy assessments showed that the
addition of bromocriptine to standard heart failure therapy in
women with PPCM appeared to result in significantly greater
improvements in NYHA functional class, LV systolic and
diastolic function, and degree of functional mitral regurgita-
tion than seen with standard therapy alone. Bromocriptine
seemed to be well tolerated, and no thrombotic complications
were observed. Moreover, although bromocriptine stopped
lactation and breast-feeding in the PPCM patients, the growth
and survival of those infants were normal. However, our
study was very small, and these findings are in no way
definitive. On the other hand, these findings are encouraging
and suggest that a larger study should be considered.
This proof-of-concept pilot study was performed in a group
of homogeneous patients in terms of ethnic background, age,
time point of diagnosis, and baseline characteristics. Unfor-
tunately, blinding of the study was not possible because the
PPCM-Std group continued to nurse their infants while the
PPCM-Br group could not breast-feed because of
bromocriptine-induced cessation of lactation. However, in-
vestigators were blinded for data analysis. We believe that the
homogeneous patient cohort, well-balanced baseline charac-
teristics, and blinded assessment of outcomes to some extent
compensate for the small size of our study and its open-label
design.
The design of the present study was chosen on the basis of
our hypothesis that a cleaved form of the hormone prolactin
initiates and drives PPCM and that early pharmacological
blockade of prolactin with bromocriptine may improve the
condition of patients with acute onset of PPCM before
irreversible damage caused by cell death, fibrosis, and remod-
eling. Increased serum levels of 16-kDa prolactin and aug-
mented cathepsin D activity at baseline in PPCM patients
included in the present study support this hypothesis. The
rationale for the dose and length of bromocriptine therapy
was based on previous observations in animal models and a
previous pilot study,11 as well as several case reports in
patients with PPCM.12,23,24 We believe that some of the
apparently beneficial effects of bromocriptine result from
eliminating the detrimental 16-kDa prolactin form, the harm-
ful effects of which on the heart and the vasculature have
been described experimentally.11,24 In addition, both forms of
prolactin promote inflammation,24 a reaction that seems to be
associated with PPCM in this African cohort, because most
patients displayed increased serum levels of the inflammatory
marker hsCRP.5
Figure 2. Change in LVEF from baseline to 6 months among
survivors. Stars represent baseline LVEF for patients who died
during the study period.
Table 4. Comparison of NYHA Functional Class in PPCM-Br




















I 0 9 (100) 0 0
II 5 (50) 5 (50) 3 (50)
III/IV 5 (50) 5 (50) 3 (50)
*Comparing the change from baseline to 6 months in PPCM-Br and
PPCM-Std patients.
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Apart from its prolactin blocking role, bromocriptine may
exert additional “off-target effects” in PPCM patients. For
example, effects of bromocriptine on hemodynamic parame-
ters in patients with heart failure were described 30 years
ago25 before treatment with ACE inhibitors and -blockers
was routine. Positive effects of bromocriptine on blood
pressure, vascular resistance, and plasma norepinephrine
levels have been described.25 Moreover, bromocriptine has
been shown to increase stroke volume index and to decrease
LV filling pressure.25,26 Whether these potential beneficial
effects of bromocriptine on hemodynamic parameters play a
role in contemporary patients with heart failure who are
treated with ACE inhibitors and -blockers remains to be
elucidated.
Bromocriptine may also affect metabolic parameters. We
observed that PPCM patients display increased oxidized
low-density lipoprotein serum levels compared with healthy
postpartum women,9 suggesting impaired antioxidative de-
fense mechanisms and potential metabolic perturbations. In
turn, Wexler and McMurtry 27 reported that, experimentally,
bromocriptine treatment reduced triglyceride, free fatty acid,
total cholesterol, and glucose levels in isoproterenol-induced
heart failure. Whether such parameters play a role in the
pathophysiology of PPCM is currently under investigation in
experimental models.
In addition, bromocriptine has been shown to inhibit
oxidative stress–induced cell death in neuronal cells by
dopamine D2 receptor–dependent transactivation of c-Src/
endothelial growth factor receptor and downstream PI3K-Akt
signaling, which results in upregulation of antiapoptotic
Bcl-2.28 Preliminary data show that bromocriptine treatment
increases Akt activation and upregulates Bcl-2 expression in
the heart of postpartum mice (D.H.-K., unpublished data,
2010), suggesting that bromocriptine may indeed have direct
cardioprotective effects. Taken together, these data show that
off-target effects of bromocriptine on metabolism, oxidative
stress, and cytoprotection may act in concert with its
prolactin-lowering capacity and may help to explain the
positive effects of prolonged treatment with bromocriptine
beyond an effective prolactin blockade.
We found that the overall mortality rate in the PPCM-Std
group was high. Other studies have demonstrated a lower
PPCM mortality rate (averaging 15%), including our own
series of 100 patients1,5,8 and the prospective long-term study
by Fett et al.4 One explanation for the differences in mortality
rate between the present study and our other series of 100
patients might be the inclusion criteria. In the present study,
patients were enrolled very early (within 24 hours after
diagnosis). This timely enrollment was not possible for the
previous cohort of 100 patients. As a consequence, some
patients in that study died between diagnosis and enrollment.
In addition, our previous study included patients diagnosed
Figure 3. Comparison of 6-month prespecified poor outcome,
including death, NYHA functional class (FC) III/IV, and LVEF
35% among survivors, and the combined end point includ-
ing all 3 of these end points for PPCM-Br vs PPCM-Std
patients (Pt).
Figure 4. Cardiac MRI (transverse view, steady-state free-
precession sequence) in a young African woman 2 months after
delivery demonstrates marked dilation of both ventricles and the
right atrium. LVEF is 8%.
Table 5. Comparison of Laboratory Parameters in PPCM-Br and PPCM-Std Patients at Baseline and 6 Months
PPCM-Br at Baseline
(n10)




PPCM-Std at 6 mo
(n6) P†
Hemoglobin, g/dL† 13.02.2 12.71.5 11.81.9 13.01.4 0.58
Creatinine, mol/L‡ 71 (6–109) 78 (52–113) 66 (5–96) 62 (41–73) 0.86
hsCRP, mg/L‡ 7.8 (1.1–58.0) 4.7 (1.0–10) 6.0 (4.0–115.3) 1.8 (1.1–15.1) 0.18
Prolactin, g/L‡ 49.9 (3.8–135.0) 8.0 (5.9–25.0) 30.0 (5.1–233.0) 12.5 (7.4–60.0) 0.72
Log NT-proBNP† 8.541.14 5.620.80 8.451.24 6.640.60 0.056
*Comparing the change from baseline to 6 months in PPCM-Br and PPCM-Std patients.
†Values are mean1SD.
‡Values are median (range).
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between 4 weeks and 5 months postpartum. The development
of symptoms 4 weeks postpartum may be a manifestation
of milder forms of this disease.
In this study, the cause of death in the PPCM-Std group
was either heart failure or sudden cardiac death, with all
deaths occurring within 3 months of randomization. In
contrast, the 1 patient who died in the PPCM-Br group was
admitted with severe heart failure and died 7 days after
diagnosis while still in the intensive care unit.
The safety of bromocriptine treatment during pregnancy
has already been assessed by a survey of 1400 pregnant
women who took bromocriptine primarily in the first few
weeks of pregnancy and found no increased rates of abortion
or congenital malformations.29 In the postpartum phase,
bromocriptine has been used worldwide since 1980 to sup-
press lactation. However, concerns have been raised about a
potential risk for cerebral and cardiovascular complications,
as emphasized in some case reports describing stroke,13
seizure,15 coronary artery thrombosis,15 and coronary artery
vasospasm.14 Although these data were observational, bro-
mocriptine was withdrawn from the market in the United
States in 1994 for use as an agent to block lactation.
It is known that the postpartum period is associated with an
increased risk of thrombosis and myocardial infarction, prob-
ably because of changes in coagulation that may have
evolved as a protection from bleeding caused by miscarriage
and childbirth.30 We observed no adverse effects in any of the
9 surviving patients in the PPCM-Br group. However, the
number of patients studied was small, and because of poor
cardiac function, all patients in the present study received
subcutaneous low-molecular-weight heparin during their in-
dex admission. Therefore, although the data suggesting that
bromocriptine has a prothrombotic effect are not robust, we
cannot rule out such an effect.
There has been some concern that PPCM patients in
developing countries treated with bromocriptine will no
longer be able to breast-feed, which may increase the risk for
malnutrition and infection in their infants.17 The survival rate
of infants of the PPCM-Br patients was not affected, and no
serious illnesses were reported, although the number of
children we studied was very small. Normal weight gain from
birth to 3 months was observed in all infants and continued to
be normal during the 6-month follow-up period in those for
whom data were available. Although this was a small study
with only short-term follow-up, our results suggest no disad-
vantage to the infant of a PPCM patient who could not
breast-feed because of bromocriptine treatment. However, we
are aware that larger studies in Soweto and other developing
areas in the world are needed to support this statement.
Conclusions
In this trial, the addition of bromocriptine to standard heart
failure therapy appeared to improve LVEF and a composite
clinical outcome in women, although the number of patients
studied was small and the results cannot be considered
definitive. Larger-scale multicenter and blinded studies are in
progress to test this strategy more robustly.
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CLINICAL PERSPECTIVE
Peripartum cardiomyopathy (PPCM) is a potentially life-threatening heart disease that occurs in previously healthy women. We
identified prolactin, mainly its 16-kDa angiostatic and proapoptotic form, as a key factor in PPCM pathophysiology. Blockade
of prolactin with the dopamine-2D agonist bromocriptine had previously been shown to prevent the onset of PPCM in mice and
in women at high risk of this condition because of documented PPCM in a previous pregnancy. We recruited 20 women with
onset of severe acute PPCM during the first month postpartum within 24 hours of diagnosis and randomized them into 2 groups:
standard care (PPCM-Std; n10) or standard care plus bromocriptine for 8 weeks (PPCM-Br, n10). PPCM-Br patients
displayed greater recovery of left ventricular ejection fraction compared with PPCM-Std patients at 6 months. Four PPCM-Std
patients died; only 1 PPCM-Br patient did not survive. Significantly fewer PPCM-Br patients met the composite end point of
poor outcome defined as death, New York Heart Association functional class III/IV, or left ventricular ejection fraction 35%
at 6 months. Because the PPCM-Br mothers could not breast-feed, the outcome of their children was assessed. Infants of mothers
in both groups showed normal growth and survival at 6 months. Our findings suggest that the addition of bromocriptine to
standard heart failure therapy appears to improve left ventricular ejection fraction, functional class, and survival in women with
severe acute PPCM with no obvious detriment to their children.
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Correction
In the article, “Evaluation of Bromocriptine in the Treatment of Acute Severe Peripartum
Cardiomyopathy: A Proof-of-Concept Pilot Study” by Sliwa et al, which appeared in the April 6,
2010 issue of the journal (Circulation. 2010;121:1465–1473), there was a misspelling of one
author’s name. Ingrid Struhman should be spelled Ingrid Struman.
The online version of the article has been corrected. The authors regret the error.
DOI: 10.1161/CIR.0b013e3181e3a433
(Circulation. 2010;121:e425.)
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